Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

Ads

You May Also Like

iCAD Announces Retirement of CEO, Ken Ferry

Michael Klein, Chairman of the Board, to serve as Executive Chairman and Interim CEO ...

electroCore Expands Manufacturing Capabilities for gammaCore™

BASKING RIDGE, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage ...

Genocea Biosciences Reports Second Quarter 2017 Financial Results

- Recently reported positive top-line 12-month Phase 2b data for GEN-003 in genital herpes ...